Loading stock data…
$1.10+0.00 (+0.28%)
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Cellectis S.A. in the Healthcare sector is trading at $1.10 with a market capitalization of $162M. Wall Street consensus targets $4.83 (4 analysts), implying a +337.4% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 66.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.23M↓ | $5.78M↓ | $10.40M↓ | $35.17M↑ | $16.73M |
| Gross Profit | $2.87M↓ | $3.46M↓ | $7.40M↓ | $32.81M↑ | $14.30M |
| Operating Income | -$23.52M↑ | -$25.17M↓ | -$17.35M↓ | $8.04M↑ | -$9.59M |
| Net Income | -$21.82M↓ | -$17.77M↑ | -$26.32M↓ | $589,000↑ | -$23.74M |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates...